You are here:

glycopyrronium (Seebri Breezhaler)

Advice

Following a full submission:

glycopyrronium inhalation powder (Seebri Breezhaler®) is accepted for use within NHS Scotland.

Indication under review: as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

In two phase III studies, glycopyrronium was statistically superior to placebo in improving lung function (forced expiratory volume in 1 second [FEV1]) after 12 weeks.

Drug Details

Drug Name: glycopyrronium (Seebri Breezhaler)
SMC Drug ID: 829/12
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: For a once daily maintenance bronchodilator treatment to relieve symptoms in patients with COPD.
BNF Category:
Sub Category: 3.1 Bronchodilators
Submission Type: Full submission
Status: Accepted
Date Advice Published: 14 January 2013

Back